Elsevier

Contraception

Volume 66, Issue 1, July 2002, Pages 33-40
Contraception

Original research article
Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India

https://doi.org/10.1016/S0010-7824(02)00309-8Get rights and content

Abstract

As several important policy questions remain regarding the use of medical abortion in developing countries, we investigated the safety, efficacy, and acceptability of mifepristone-misoprostol abortion in the outpatient family planning departments of two urban hospitals and one rural hospital in India. Nine-hundred women (with gestations of ≤63 days in the urban sites and ≤56 days in the rural site) received 600 mg mifepristone followed 48 h later by 400 μg oral misoprostol in the clinic. Four point four percent or fewer urban women and 1.0% rural women were lost to follow-up. Perfect and typical-use failure rates were low at all sites. While rural women reported fewer side effects at all sites, the vast majority of women were satisfied with their medical abortions. Medical abortion can be offered safely, effectively, and acceptably in the outpatient family planning departments of urban and rural hospitals in India.

Introduction

Mifepristone medical abortion offers a safe and acceptable non-surgical alternative to women seeking early pregnancy termination [1], [2]. In Europe alone, where the method has been available in three countries (France, Sweden, and UK) for nearly 10 years, more than 750,000 women have used it. Recent mifepristone approvals in several additional European countries and introduction in the US in 2000 should lead to a large increase in the number of developed-country women with access to this method of abortion.

In the developing world, however, where nearly all of the 70,000 estimated deaths each year because of unsafe abortion occur [3], mifepristone is readily available in only a single country, China. In recent years, policymakers and women’s health advocates have called for the increased availability of medical methods of abortion in developing countries, and Ministries of Health from several such countries have expressed interest in their introduction [4], [5]. While recent studies have explored the use of this method in other developing countries [6], [7], [8], four key questions about the method’s use in such settings remain unanswered: (1) Can mifepristone abortion be offered safely and effectively in existing urban family planning clinics? All previous studies were conducted in research settings. (2) Can the method be provided in a rural setting? While 63% of developing-country women live in rural areas [9] where access to abortion services is particularly difficult, no study has documented the use of mifepristone in such settings. (3) Is mifepristone-misoprostol as acceptable to rural women as to urban women? Given socioeconomic and cultural differences between rural and urban women, results of studies conducted in urban environments may not be applicable to rural ones. (4) Is the method safe, effective, and acceptable up to 9 weeks gestation? To date, the studies conducted in developing countries have assessed the method’s safety, efficacy, and acceptability up to 8 weeks gestation. Given the logistic delays women encounter when seeking abortions in many developing countries, if safe, effective, and acceptable, extending the gestational age cut-off by 1 week would greatly increase access to the method. We conducted a study of mifepristone-misoprostol abortion in two urban and one rural setting in India to address these questions.

Abortion has been legally available in India since 1972. Nonetheless, access to legal abortion services there remains difficult. In 1996, with population estimates exceeding 900 million, only approximately 8500 facilities were approved to provide abortion [10]. In certain states, such as Uttar Pradesh, there were only 3.4 approved centers per million population. While the approved facility-to-population ratio was higher in other states, many centers in those states lacked the necessary equipment or trained personnel to provide consistent abortion services. Indeed, in 1996 less than 5% of the 1646 approved centers in Maharashtra state were functioning [10]. Additionally, abortion services in rural areas are particularly short-changed. Finally, many of the surgical abortion services in India are marked by a number of quality problems. Ultimately, complications of abortion account for approximately 12% of all maternal deaths in India [11].

Section snippets

Methods

We conducted a prospective study from August 1995 to September 1998 in the outpatient family planning departments of two urban hospitals (Pune and Mumbai) and one rural hospital (Vadu) in the Indian state of Maharashtra. While Pune and Mumbai are large metropoles, Vadu is a village of 56,000 located 30 kilometers from Pune. As part of a larger project to increase access to healthcare in the rural areas surrounding Pune, the Vadu hospital serves women from a well delineated rural area. The two

Sample characteristics

The sample included 900 women, 300 at each of the three study sites (Table 1). Vadu women were the youngest (Vadu 23.8 years, Pune 26.7 years, Mumbai 26.4 years), shortest (Vadu 151.1 cm, Pune 155.4 cm, Mumbai 152.1 cm), and weighed the least (Vadu 44.3 kg, Pune 51.9 kg, Mumbai 49.6 kg). The rural women also averaged fewer years of schooling than urban women, although even between the two urban sites, there was a significant difference in education levels (Vadu 8.4 years, Pune 13.0 years,

Discussion

Our findings suggest that mifepristone-misoprostol abortion can be safely, effectively, and acceptably offered in urban family planning departments and rural health settings in India. While highest in the rural hospital, perfect-use success rates exceeded 91.0% in the two urban facilities where women up to 9 weeks gestation participated. When user failures were considered as well, efficacy rates changed minimally, suggesting that both urban and rural women can adhere to a medical abortion

Acknowledgements

The authors are extremely grateful to Andrea Eschen for valuable assistance at the initiation of the study, and Sunil Patel for extensive efforts on data entry and cleaning. The authors also thank Elizabeth Pearlman for her assistance with preliminary table preparation.

References (11)

There are more references available in the full text version of this article.

Cited by (34)

  • Women's voices and medical abortions: A review of the literature

    2020, European Journal of Obstetrics and Gynecology and Reproductive Biology
    Citation Excerpt :

    In the absence of clinical confirmation of the abortion, some of the women thought their abortion had ‘failed’ because they had not bled enough (pg. 4) [6]. There were other inconveniences as well, such as the expulsion of the products of conception in a public space and in one case, in transit [30]. Overall, it seems that in Euro-American countries, where abortion is legal, offering women the choice of abortion methods increases their general satisfaction, regardless of the method [17,18,23].

  • Medical abortion: Understanding perspectives of rural and marginalized women from rural South India

    2012, International Journal of Gynecology and Obstetrics
    Citation Excerpt :

    Mifepristone and misoprostol are licensed for MA in India—mifepristone was approved in 2002—and studies have shown that the method is highly acceptable to Indian women. Opting for medical or surgical abortion depends, in part, on the woman's socioeconomic situation; her perception of the degree and duration of interference with her domestic and childcare duties that each method would bring; and the amount of support available to her from family members [3,13]. While women choose abortion based on their different needs, research on MA in India has largely focused on the perspectives of providers and urban women.

  • Home administration of misoprostol for early medical abortion in India

    2010, International Journal of Gynecology and Obstetrics
View all citing articles on Scopus

This study was funded by an anonymous donor.

View full text